This week’s clinical pharmacology highlights include a new treatment for river blindness, further success for JAK inhibitors in inflammatory diseases, and the finding that more patients are taking medications associated with depressive symptoms.
Moxidectin – River Blindness
- June 13th: The FDA has approved the antihelminthic agent Moxidectin – a glutamate receptor (GluCl) and GABAA receptor modulator – for the treatment of onchocerciasis (river blindness) due to Onchocerca volvulus infection in patients aged 12+. Moxidectin was previously approved only for veterinary use.
Suboxone Generic – Opioid Use Disorder
- June 13th: The FDA has approved a generic buprenorphine/naltrexone (Suboxone) sublingual film for the treatment of opioid use disorder. Generic sublingual buprenorphine/naltrexone sublingual tablets have been available for several years.
Upadacitinib – RA
- June 13th, The Lancet: Two phase III trials (SELECT-NEXT & SELECT-BEYOND) of upadacitinib, a selective JAK1 inhibitor for the treatment of refractory rheumatoid arthritis showed efficacy and a reasonable safety profile. Randomized-placebo controlled.
Baricitinib – SLE
- June 14th, Annual European Congress of Rheumatology: A phase II clinical trial of baricitinib (JAK1/JAK2 inhibitor) has demonstrated efficacy in the treatment of systemic lupus erythematosus. Randomized-placebo controlled.
Ozenoxacin – Impetigo
- June 13th, JAMA Dermatology: A phase III trial showed Ozenoxacin (non-fluorinated quinolone antibiotic) 1% topical cream is safe and efficacious in childhood impetigo infection. Drug was approved last year for impetigo, based in part on these results. Randomized-placebo controlled.
Aramchol – NASH
- June 12th, Galmed Pharmaceutical: A phase II clinical trial of aramchol (SCD1 modulator) showed efficacy in treating non-alcoholic steatohepatitis (NASH) and will likely move to Phase III trials. Randomized placebo-controlled.
Amisulpride – Nausea
- June 14th, Anesthesiology: A clinical trial has demonstrated that IV administration of the antipsychotic amisulpride (a dopamine antagonist) alongside a second antiemetic is effective in preventing post-op nausea & vomiting. Randomized placebo-controlled.
Clinical Pharmacology Research
Antibiotics – Appendicitis
- June 13th, Annals of Surgery: A cohort study found that narrow-spectrum antibiotics are just as effective as broad spectrum antibiotics (e.g., pip-tazo) in children with uncomplicated appendicitis. Observational retrospective cohort.
Fluconazole – Stillbirth
- June 13th, JAMA: A study observed that oral fluconazole use in pregnancy did not significantly increased risk of stillbirth or neonatal death. Observational retrospective cohort.
Medications – Depression
- June 12th, JAMA: A population study found that 37% of patients (from NHANES database) use medications associated with causing depressive symptoms. Observational cross-sectional.
Betamethasone – Cardiometabolic Outcomes
- June 9th, Pediatrics: The ACTORDS trial demonstrated that antenatal betamethasone (steroid used for accelerating fetal organ development) in women at risk for pre-term birth was not associated with adverse childhood cardiometabolic outcomes, and may have a beneficial effect on height. Randomized-controlled.
Give us feedback at email@example.com, on Twitter (@thepharmareview) or on Facebook (The Pharmacology Review).